Biotechnology Division
De Amertek is currently expanding its strategic capabilities through the development of a dedicated Biotechnology Division, focused on advancing next-generation cell-based technologies and translational biomedical innovation. This new division is designed to serve as a platform for scientific collaboration, and long-term product development and commercialization within the global life sciences ecosystem.
As the cornerstone of this initiative, De Amertek is introducing Amniotic Fluid–Derived Stem Cells (AFSCs) as its flagship technology. AFSCs will serve as the foundational product supporting future research collaborations, technology licensing opportunities, and downstream biomedical applications.
Product Overview
Amniotic Fluid–Derived Stem Cells (AFSCs) are a unique population of multipotent stem cells isolated from human amniotic fluid. These cells combine key biological advantages of embryonic-like plasticity with the safety profile and ethical acceptability associated with non-embryonic cell sources.
Scientific Characteristics
AFSCs exhibit multipotent differentiation capacity, high proliferative potential, low immunogenicity, and genomic stability, making them suitable for advanced biomedical research.